Analyst Price Targets — CRVO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 18, 2026 9:34 pm | — | Roth Capital | $9.00 | $3.04 | TheFly | CervoMed price target lowered to $9 from $11 at Roth Capital |
| November 5, 2025 11:14 am | Raghuram Selvaraju | H.C. Wainwright | $25.00 | $7.02 | TheFly | CervoMed upgraded to Buy from Neutral at H.C. Wainwright |
| October 17, 2025 10:25 am | — | Roth Capital | $20.00 | $7.60 | TheFly | CervoMed price target raised to $20 from $16 at Roth Capital |
| August 12, 2025 11:59 am | Boobalan Pachaiyappan | Roth Capital | $16.00 | $9.41 | TheFly | CervoMed price target lowered to $16 from $20 at Roth Capital |
| September 18, 2024 5:17 am | Danill Gataulin | Loop Capital Markets | $16.32 | $4.79 | StreetInsider | Chardan Capital Markets Starts CervoMed (CRVO) at Buy |
| September 18, 2024 5:05 am | Daniil Gataulin | Chardan Capital | $16.32 | $4.79 | TheFly | CervoMed initiated with a Buy at Chardan |
| April 8, 2024 7:06 am | Sumant Kulkarni | Canaccord Genuity | $19.29 | $6.08 | StreetInsider | CervoMed (CRVO) PT Raised to $65 at Canaccord Genuity |
Latest News for CRVO
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain atrophy, as well as optimal dosing strategies
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share.
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in a registered direct offering priced at-the-market under…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRVO.
U.S. House Trading
No House trades found for CRVO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.